Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 12/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408320 | 0.86 | MTNR1B (0.45) | MTNR1BMTNR1A | |
| SCHEMBL6409567 | 0.82 | MTNR1B (0.42) | MTNR1BMTNR1A | |
| SCHEMBL6408595 | 0.82 | MTNR1B (0.56) | MTNR1BGPR119MTNR1ANPC1RAB9A | |
| SCHEMBL6422049 | 0.78 | MTNR1B (0.73) | MTNR1BMTNR1ANPC1RAB9A | |
| SCHEMBL6409459 | 0.78 | MTNR1B (0.54) | MTNR1BGPR119MTNR1ANPC1RAB9A | |
| SCHEMBL6409482 | 0.77 | MTNR1B (0.52) | MTNR1BGPR119MTNR1A | |
| SCHEMBL6403218 | 0.76 | MTNR1B (0.50) | MTNR1BGPR119MTNR1A | |
| SCHEMBL6407452 | 0.76 | MTNR1B (0.52) | MTNR1BGPR119MTNR1A | |
| SCHEMBL6405918 | 0.74 | MTNR1B (0.54) | MTNR1BMTNR1ANPC1RAB9A | |
| SCHEMBL6409504 | 0.74 | MTNR1B (0.49) | MTNR1BGPR119MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | MTNR1B 63/4885GPR119 203/4885MTNR1A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.